Looking for advanced melanoma patients to test the safety and effectiveness of the combined treatment pembrolizumab with vemurafenib
In a nutshell
This trial aims to test safety and effectiveness of the combined treatment with pembrolizumab (Keytruda) and vemurafenib (Zelboraf) in patients with stage 3 or 4 melanoma. The main outcome to be measured will be the response of the tumors to the treatment. This trial is recruiting in Pittsburgh, Pennsylvania (US).
The details
Tumors with a mutation (permanent change) in the BRAF gene are more aggressive. Pembrolizumab inhibits (blocks) BRAF and stimulates the immune system to kill melanoma cells. Vemurafenib is also a BRAF inhibitor that blocks tumor growth. A combination of these two therapies could significantly benefit the patient. However, it is not clear whether they are safe and effective when used in combination.
The current trial will examine combination treatment with pembrolizumab and vemurafenib in patients with advanced melanoma. The main outcome will be measured through tumor response to the treatment and response of the immune system.
Who are they looking for?
This trial will recruit 50 participants with stage 3 and 4 melanoma that cannot be surgically removed. Patients must have a BRAF mutated tumor. Participants must have normal blood values. Participants must not have brain metastasis, cardiovascular disease, autoimmune diseases, pulmonary disease, or bowel disease. Female participants must not be pregnant or breastfeeding, and must agree to use contraception. Participants must not have been treated with BRAF inhibitors before, and must not be using therapies that suppress the immune system.
How will it work
Patients will be treated with pembrolizumab (200 mg) every 3 weeks. Vemurafenib will be given at 480, 720 or 960 mg twice daily. Both therapies will start on the same day. Patients will be followed for up to 2 years or until tumor progression or death. The change in the immune-related overall response rate will be determined following the last treatment and safety will be assessed by the number of patients with severe side effects.
Recruiting
Name
City, Country
Clinical trial locations
Please enter zip/postal code and country to help us offer locations near you
UPMC Cancer Center Hillman Cancer Center
Pittsburgh, United States
Apply to clinical trial
Looking for advanced melanoma patients to test the safety and effectiveness of the combined treatment pembrolizumab with vemurafenib
Apply to clinical trial
Looking for advanced melanoma patients to test the safety and effectiveness of the combined treatment pembrolizumab with vemurafenib
This doesn't look like a valid phone number. Please check.
Both First Name and Last Name are required. Please check.
Sorry you missed this one, the trial is no longer recruiting.
Disclaimer:
This information should not be relied upon as a substitute for personal medical advice, diagnosis or treatment. Use the information provided by Medivizor solely at your own risk. Medivizor makes no warranties or representations as to the accuracy of information provided herein. If you have any concerns about your health, please consult a physician.
Discussion about this item
Bud
Mar 07, 2018
at present I have no melanoma reacurances.Many squamous cell and baseline cell present.
Reply
You can discuss this item with other users. Before entering the discussion, please let us know if the item seems helpful by clicking 'Helpful?' and submitting your response. We appreciate it and it helps Medivizor tune it's system to get you more relevant and helpful information.
at present I have no melanoma
reacurances.Many squamous cell and baseline cell present. Reply